Menstrual Control with Levonorgestrel IUD

Introduction to Menstrual Control Options

• The American Academy of Pediatrics recommends the levonorgestrel-releasing intrauterine system (LNG-IUS) for women requiring long-term menstrual suppression when estrogen is contraindicated 1
• The Society of Family Planning guidelines recommend IUDs as preferred first-line contraceptive options for women with contraindications to estrogen-containing methods 2

Clinical Implementation

• Perform bimanual examination and cervical inspection before insertion, and screen for sexually transmitted infections according to current guidelines 3, 4, 5, 6
• Confirm the patient is not pregnant using standard criteria 3, 5
• The LNG-IUS can be inserted at any time if reasonably certain the patient is not pregnant 3, 5, 7, 8

Managing Breakthrough Bleeding

• Prescribe NSAIDs for 5-7 days during bleeding episodes as first-line treatment for breakthrough bleeding in the first 3-6 months 6, 9
• Consider short-term hormonal treatment with low-dose combined oral contraceptives or estrogen for 10-20 days if bleeding persists beyond 6 months 9

Advantages Over Other Options

• Long-acting reversible contraception (LARC) methods like the LNG-IUS are superior to short-acting contraceptives in young women, with 12-month adherence rates of 86% versus 55% for oral contraceptive pills 2
• The contraceptive failure rate for oral pills is significantly higher than LARC (4.55 vs 0.27) 2
• Daily pill-taking introduces adherence challenges that compromise both contraceptive efficacy and menstrual control 1

Mirena Insertion Guidelines

Contraindications and Pre-Insertion Requirements

• The Centers for Disease Control and Prevention recommends ruling out anatomical abnormalities that would distort the uterine cavity, as these are absolute contraindications (Category 4) to IUD insertion, and assessing for uterine fibroids, which may increase expulsion rates 10
• The Centers for Disease Control and Prevention states that current pelvic inflammatory disease, purulent cervicitis, chlamydia, or gonorrhea are absolute contraindications to IUD insertion, and treatment with antibiotics should be completed first 10
• The Centers for Disease Control and Prevention recommends that distorted uterine cavity from congenital or acquired abnormalities, and current cervical or endometrial cancer awaiting treatment are absolute contraindications to IUD insertion 10
• The Centers for Disease Control and Prevention classifies past PID without subsequent pregnancy as a relative contraindication (Category 2), and current breast cancer as a Category 4 contraindication for hormonal methods, though concerns may be less with LNG-IUD 10

Clinical Advantages and Patient Counseling

• The American Heart Association, as published in Circulation, notes that the LNG-IUS can reduce menstrual blood loss by 71-95%, making it comparable in effectiveness to endometrial ablation for heavy menstrual bleeding 11
• The American Heart Association, as published in Circulation, states that systemic progesterone absorption is minimal with the LNG-IUS, making it safer than systemic hormonal options in women with cardiovascular concerns 11

Mirena IUD Contraindications and Safety Considerations

Absolute Contraindications (Category 4)

• Pregnancy (confirmed or suspected) – Insertion of the levonorgestrel‑releasing IUD in pregnant individuals carries a high risk of severe pelvic infection and septic spontaneous abortion; therefore, pregnancy is the sole absolute contraindication. [CDC 12]
• Current breast cancer – Because breast cancer is hormonally sensitive, the levonorgestrel IUD is contraindicated in women with active disease. [CDC 12]
• Persistently elevated β‑hCG or malignant gestational trophoblastic disease – Ongoing high β‑hCG levels or malignant trophoblastic disease preclude IUD placement. [CDC 12]
• Current cervical or endometrial cancer awaiting treatment – Insertion may increase infection, perforation, and bleeding risks, and the device will likely need removal during cancer treatment. [CDC 12]

Relative Contraindications (Category 3)

• History of breast cancer with ≥5 years disease‑free interval – While not an absolute barrier, clinicians should consider the reduced progression risk with the LNG‑IUD compared with combined oral contraceptives. [CDC 12]
• Unexplained vaginal bleeding pending evaluation – Initiation is Category 4 (deferred) until pathology is ruled out; continuation after evaluation is Category 2, and the device does not require removal before work‑up. [CDC 12]

Category 2 Conditions (Advantages Generally Outweigh Risks)

• Cervical intraepithelial neoplasia (CIN) – Theoretical concern exists that the LNG‑IUD could promote CIN progression, but evidence is limited; benefits usually outweigh potential risks. [CDC 12]
• Undiagnosed breast mass – Requires diagnostic evaluation but does not constitute an absolute contraindication to IUD use. [CDC 12]
• Heavy or prolonged menstrual bleeding (menorrhagia) – The LNG‑IUD is effective for treating menorrhagia; initiation is placed in Category 2. [CDC 12]

Clinical Pitfalls (Not Contraindications)

• Past pelvic inflammatory disease, HIV infection, immunosuppression, and nulliparity – These factors are not contraindications; the risk of pelvic infection is confined to the first 20–21 days after insertion. [CDC 12]

Safety Warnings

• Gestational trophoblastic disease with decreasing β‑hCG – Classified as Category 3; it is not an absolute contraindication to Mirena insertion. [CDC 12]

CDC Medical Eligibility Criteria for Intrauterine Device (IUD) Insertion

Absolute Contraindications

• A distorted uterine cavity caused by anatomical abnormalities that prevent proper device placement is classified as a Category 4 (absolute) contraindication to IUD insertion according to the CDC Medical Eligibility Criteria. 13

Relative Contraindications / Considerations

• The presence of uterine fibroids may increase the risk of IUD expulsion but is considered a Category 2 (generally safe) condition, not a contraindication to insertion. 13

• Cervical stenosis, which can be encountered in nulliparous patients, does not constitute a contraindication; it is also classified as Category 2, indicating that insertion may proceed with appropriate technique (e.g., cervical preparation). 13

Expulsion Risk in Adenomyosis

• In women with adenomyosis and an enlarged uterus, IUD expulsion rates are higher, reported at 11 %–20 % in some series, compared with 0 %–3 % in women with normal‑sized uteri. This elevated risk should be communicated to patients and managed with appropriate follow‑up. 13

Levonorgestrel IUD: Pharmacokinetics and CDC Eligibility Guidelines for Nulligravida Women

Pharmacokinetic Advantage

CDC Eligibility for Nulligravida and Virgin Women

Pre‑Insertion Assessment (CDC Recommendations)

Insertion Timing (CDC Recommendations)